N/A
N=42
755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars
Benign Pigmented and Vascular Lesions and Scars
Bottom Line
View on ClinicalTrials.gov: NCT01745627 ↗Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- 755nm Alex laser (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cynosure, Inc.
- Primary completion
- Dec 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clearance Based on Photographic Scale |
2; 2; 4; 5 | — |
| PRIMARY Clearance Based on Photographic Scale |
2; 2; 4; 5 | — |
Summary
Evaluation of the safety and efficacy of the 755nm Alex laser for the treatment of benign pigmented and vascular lesions and scars
Eligibility Criteria
Inclusion Criteria
- Healthy male or female subjects between 18 and 85 years of age.
- Subjects with Fitzpatrick skin types I to VI.
- Subjects who have unwanted pigmented lesions, vascular lesions, striae and/or hypertrophic or atrophic scars
- Subject who are willing to consent to participate in the study.
4.2 Exclusion Criteria
- Subject who will not be photographed or who will not cooperate with the post treatment care and follow up schedule
- Hypersensitive to light exposure.
- Active localized or systemic infections.
- Taking medication for which sunlight is a contraindication.
- History of squamous cell carcinoma or melanoma.
- History of keloid scarring.
- Use of oral isotretinoin (Accutane®) within 12 months of initial treatment or during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment.
- Prior treatment with laser or other devices in treatment area within 3 months
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications.
- Subjects who are pregnant, have been pregnant within the last 3 months, are currently breast feeding or are planning a pregnancy within the study period.
- Subjects that the physician determines ineligible based on standard of care treatment.
-
-
Data sourced from ClinicalTrials.gov (NCT01745627). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.